Short answer: there is no human SR9009 (Stenabolic) dosage from research. SR9009 has never been tested in people. Users most often report 20–30 mg a day split into two or three doses, taken before late afternoon. The research doses were in mice, given by injection at 100 mg per kg of body weight twice a day (Solt 2012), which cannot be converted into a human dose.

20–30 mg

a day, split into two or three doses: what users most often report

100 mg per kg

of body weight, injected twice a day: the research dose in mice

This guide covers what the mouse studies found, what users report for cutting and bulking, the half-life question, and the liver-injury case reports you should know about. The full compound profile is in our Stenabolic review.

SR9009 Summary

SR9009 (Stenabolic) is not a SARM. It is a synthetic activator of REV-ERB, a protein in the body clock that also controls fat and sugar metabolism genes in the liver, muscle and fat tissue (Solt 2012).

Effect What was found Evidence
Fat and metabolism Injected into obese mice, it reduced fat mass and improved blood lipids and blood sugar; energy use rose (Solt 2012) Animal
Endurance Activating REV-ERB-alpha with SR9009 raised exercise capacity in mice; raising REV-ERB-alpha levels in muscle cells increased their mitochondria (Woldt 2013) Animal
Sleep REV-ERB agonists increased wakefulness and reduced REM and deep sleep in mice (Banerjee 2014) Animal
Off-target effects SR9009 changed cell survival and metabolism even in cells without REV-ERB, so not all its effects go through the body clock (Dierickx 2019) Cell
Liver Case reports of liver injury, including acute liver failure needing a transplant in a 17-year-old (Shams Bin Shaheen 2026) Case report
Humans No clinical trial has been published None

Note

The older version of this page said SR9009 blocks new fat cells in the liver and is a proven fat-loss compound. Those effects come from mice. Compare it with compounds that have human data in the SARMs database.

SR9009 Half-Life

The human half-life of SR9009 is not established: there are no human pharmacokinetic studies. Figures of 4–6 hours that circulate online have no published human source, and we could not verify a mouse value either. That is also why claims about very low oral bioavailability in people cannot be checked: nobody has measured it.

What is known: in the key mouse studies SR9009 was injected into the abdomen, twice a day (Solt 2012). Anti-doping labs have mapped its breakdown products using human liver enzyme preparations (Geldof 2016), but not how long it lasts in the body.

Users often split the daily amount into two or three doses, or take it under the tongue or as an injection, because they assume short action and poor absorption. None of these routes has been studied, and injecting an unapproved, unsterile product adds infection risk on top. See injectable SARMs and how to take liquid SARMs.

SR9009 Bulking Dosage + Example Cycle

Evidence level: anecdotal. SR9009 has never been given to people in a study, so the doses here are what users report, not tested doses. This is a description, not a recommendation.

SR9009 does not act on the androgen receptor, so it is not used to build muscle on its own. When people mention it in a bulk, it is usually next to a SARM such as LGD-4033:

Commonly reported (anecdotal) LGD-4033 SR9009
Weeks 1–8 2.5 mg/day 30 mg/day, split

The LGD-4033 part has human data: even 1 mg a day lowered total testosterone, SHBG and HDL in 21 days, so 2.5 mg a day is not a “no-PCT” dose (Basaria 2013). See LGD-4033 dosage.

SR9009 Cutting Dosage + Example Cycle

Evidence level: anecdotal. SR9009 has never been given to people in a study, so the doses here are what users report, not tested doses. This is a description, not a recommendation.

“Exercise in a bottle” is the nickname that comes from the mouse studies. On a cut, users most often report 20–30 mg a day, split, sometimes with ostarine:

Commonly reported (anecdotal) Ostarine SR9009
Weeks 1–8 10 mg/day 20–30 mg/day, split

What the study found: Dalton 2011

Dose
Ostarine at 1–3 mg a day
Duration
86 days
Result
already lowered total testosterone and HDL

10 mg a day has not been studied. Stacks with cardarine are also common; see cardarine before and after.

Safest SR9009 – Stenabolic Dosage

Warning

No dose of SR9009 has been shown to be safe, because none has been tested in people. Users often describe 30 mg a day as “tried and tested”, but that means it is common, not that it was studied.

Two things are worth knowing before anyone takes it:

  • Liver injury has been reported. A 40-year-old man developed hepatocellular liver injury after starting Stenabolic (Govil 2025), and a 17-year-old developed acute liver failure and needed an emergency liver transplant (Shams Bin Shaheen 2026). A liver panel (ALT, AST, bilirubin) before and during use is how problems are caught; see are SARMs liver toxic.
  • Sleep: REV-ERB agonists increased wakefulness and cut REM and deep sleep in mice (Banerjee 2014), which is why users avoid it late in the day.

What SR9009 Dosage Should I Take

We can’t give you a tested SR9009 dose, because none exists. What can be said:

  • Reported range: 20–30 mg a day split into two or three doses, finished by about 5 pm (anecdotal).
  • Women (“sr9009 for females”): there are no data in women at all; lower doses that circulate for women are guesses.
  • Liquids: the dose depends on the concentration printed on the bottle; at 10 mg per ml, 1 ml contains 10 mg. Check the label rather than assuming.
  • Products: in a 13-country survey by official medicines labs (GEON) of 324 products, mostly seized, sold as SARMs, metabolic modulators (the group SR9009 belongs to) and GH secretagogues, 24% were presented as dietary supplements (Barrios 2025); and in a US test of 44 products sold as SARMs, SR9009 was one of the unapproved drugs found instead of, or as well as, a SARM (Van Wagoner 2017).
  • Sport: SR9009 and SR9011 are named on the WADA Prohibited List (S4.4.1, metabolic modulators), banned at all times (WADA 2026).

Conclusion

Every SR9009 dosage you will read, including the 20–30 mg a day on this page, comes from users. The compound has only been tested in mice (by injection) and cells, its human half-life and absorption are unknown, and there are now case reports of serious liver injury, one ending in a transplant. If you weigh it up, treat the reported doses as reports, get liver bloodwork, and know that it is banned in sport. Related: SR9011 review and Stenabolic review.

Frequently asked questions

What is the dosage of SR9009?

No tested human doseEvidence: Animal

SR9009 has never been studied in people, so every human dose is anecdotal. In mice it was injected at 100 mg/kg twice a day, which does not translate to a human dose.

Read the full section

What is the best SR9009 dosage for cutting?

No tested cutting doseEvidence: Limited

No study has tested SR9009 for cutting in people; the doses users report for a cut are anecdotal. Fat loss was shown only in obese mice given it by injection.

Read the full section

What is the half-life of SR9009?

Not establishedEvidence: Limited

There are no human pharmacokinetic data, and the 4–6 hour figure quoted online has no published human source.

Read the full section

Does oral SR9009 work?

UnknownEvidence: Limited

Claims that it is useless orally, and that sublingual or injected forms work better, have never been tested in people. In the main mouse studies it was injected.

Read the full section

Is SR9009 safe for the liver?

Not established; warning signsEvidence: Human data

Case reports describe liver injury in a 40-year-old man and acute liver failure needing a transplant in a 17-year-old after SR9009 use.

What SR9009 dose do women take?

No data in womenEvidence: Limited

There are no data on SR9009 in women. Lower doses suggested for women online are guesses.

Read the full section

Is SR9009 banned in sport?

Yes, banned by WADAEvidence: Law

The WADA 2026 Prohibited List names SR9009 and SR9011 as Rev-erb-alpha agonists under metabolic modulators (S4.4.1), banned at all times.

Sources

  1. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists 2012 · PMID 22460951
  2. Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy 2013 · PMID 23852339
  3. Pharmacological targeting of the mammalian clock regulates sleep architecture and emotional behaviour 2014 · PMID 25536025
  4. SR9009 has REV-ERB-independent effects on cell proliferation and metabolism 2019 · PMID 31127047
  5. In Vitro Metabolic Studies of REV-ERB Agonists SR9009 and SR9011 2016 · PMID 27706103
  6. When Gains Go Wrong: A Case of Selective Androgen Receptor Modulator-Related Liver Injury 2025 · PMID 40765588
  7. Acute Liver Failure in an Adolescent Following Use of the Synthetic REV-ERB Agonist SR9009 2026 · PMID 42750938
  8. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men 2013 · PMID 22459616
  9. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial 2011 · PMID 22031847
  10. SARMs, Metabolic Modulators and Growth Hormone Secretagogues in Suspected Illegal Medicines, Bought as Sport Performance Enhancers: A Retro- and Prospective Study Within the GEON 2025 · PMID 40551438
  11. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet 2017 · PMID 29183075
  12. PubChem: SR9009 (CID 57394020), names and synonyms 2026
  13. WADA: The Prohibited List (2026 List, in force from 1 January 2026) 2026